Alan C Rapraeger
Overview
Explore the profile of Alan C Rapraeger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stueven N, Beauvais D, Hu R, Kimple R, Rapraeger A
Cancer Res Commun
. 2023 Mar;
3(1):97-108.
PMID: 36968227
Significance: A newly developed biomarker reveals upregulation of an antiapoptotic IGF1R-integrin-syndecan receptor complex in head and neck cancer and documents disruption of the complex in patient-derived tumor xenografts (PDX) treated...
2.
Beauvais D, Nelson S, Adams K, Stueven N, Jung O, Rapraeger A
J Biol Chem
. 2022 May;
298(6):102029.
PMID: 35569509
Epidermal growth factor receptor (EGFR) is a causal factor in carcinoma, yet many carcinoma patients are resistant to EGFR inhibitors. Potential insight into this resistance stems from prior work that...
3.
Rapraeger A
Front Oncol
. 2021 Nov;
11:775349.
PMID: 34778093
Receptor tyrosine kinases (RTKs) and integrin matrix receptors have well-established roles in tumor cell proliferation, invasion and survival, often functioning in a coordinated fashion at sites of cell-matrix adhesion. Central...
4.
Jung O, Beauvais D, Adams K, Rapraeger A
J Cell Sci
. 2019 Sep;
132(20).
PMID: 31562188
When targeted by the tumor-promoting enzyme heparanase, cleaved and shed syndecan-1 (Sdc1) then couples VEGFR2 (also known as KDR) to VLA-4, activating VEGFR2 and the directed migration of myeloma cells....
5.
Chen M, Choi S, Jung O, Wen T, Baum C, Thapa N, et al.
Sci Rep
. 2019 Jun;
9(1):9126.
PMID: 31235839
Epidermal growth factor receptor (EGFR) and its downstream phosphoinositide 3-kinase (PI3K) pathway are commonly deregulated in cancer. Recently, we have shown that the IQ motif-containing GTPase-activating protein 1 (IQGAP1) provides...
6.
Thapa N, Tan X, Choi S, Lambert P, Rapraeger A, Anderson R
Trends Cancer
. 2016 Nov;
2(7):378-390.
PMID: 27819060
Phosphoinositide 3-kinase (PI3K) generation of PI(3,4,5)P from PI(4,5)P and the subsequent activation of Akt and its downstream signaling cascades (e.g. mTORC1) dominates the landscape of phosphoinositide signaling axis in cancer...
7.
Sanderson R, Elkin M, Rapraeger A, Ilan N, Vlodavsky I
FEBS J
. 2016 Oct;
284(1):42-55.
PMID: 27758044
Because of its impact on multiple biological pathways, heparanase has emerged as a major regulator of cancer, inflammation and other disease processes. Heparanase accomplishes this by degrading heparan sulfate which...
8.
Beauvais D, Jung O, Yang Y, Sanderson R, Rapraeger A
Cancer Res
. 2016 Jul;
76(17):4981-93.
PMID: 27364558
Syndecan-1 (Sdc1/CD138) expression is linked to disease severity in multiple myeloma, although the causal basis for this link remains unclear. Here we report that capture of the IGF1 receptor (IGF1R)...
9.
Tan X, Lambert P, Rapraeger A, Anderson R
Trends Cell Biol
. 2016 Feb;
26(5):352-366.
PMID: 26827089
Epidermal growth factor receptor (EGFR) has fundamental roles in normal physiology and cancer, making it a rational target for cancer therapy. Surprisingly, however, inhibitors that target canonical, ligand-stimulated EGFR signaling...
10.
Wang H, Jin H, Rapraeger A
J Biol Chem
. 2015 Sep;
290(43):26103-13.
PMID: 26350464
The α6β4 integrin is known to associate with receptor tyrosine kinases when engaged in epithelial wound healing and in carcinoma invasion and survival. Prior work has shown that HER2 associates...